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In the Arena of HIV-1 Research
Since 1986, the beginning of our involvement in HIV research, our major interest was focused on
the regulation of HIV-1 replication by the transcriptional host cell machinery. Thus, we successively
investigated the consequences of inflammatory and specific responses in HIV replication in primary
monocytes and memory CD4+ T cells, and explored with special emphasis the role played by the
transcriptional factors NF-kB and the viral trans-activator Tat in the induction and maintaining
of the activity of HIV-1 promoter region, while in parallel we elucidated some of the critical
mechanisms leading to the activation of NF-kB factors.
Our initial interest in chemokines was based on our hypothesis that they could act both as
chemoattractants for HIV-1 target cells and inducers of HIV-1 transcription and replication. During
our early chemokine studies, the group of Paolo Lusso reported in 1995 that the CC chemokines
CCL5/RANTES, CCL3/MIP-1α, and CCL4/Mip-1β, isolated from an immortalized CD8+ T lym-
phocyte clone, blocked infection of a CD4+ T cell line susceptible to primary HIV-1 isolates and
some HIV-2 and SIV isolates (1). Based on the tight relationship between T cell activation and HIV
replication, the blockade of HIV infection by these factors was in an apparent contradiction with the
strong and recently reported potent antigen-independent activation in T lymphocytes by RANTES.
The Converging Paths of HIV-1 Entry and Chemokine Research
The HIV inhibitory effect of the chemokines identified by Paolo Lusso’s group was associated to
the previously known, although poorly characterized, suppressive effect of CD8+ T lymphocytes
culture supernatants (1, 2). However, the hypothesis of a possible interference of this mechanism on
HIV entry was not raised in the report. HIV entry in CD4 T lymphocytes was known to critically
rely on the interaction of the HIV envelope glycoproteins (surface subunit gp120) with CD4, a
viral receptor and a critical determinant of viral tropism, in that gp120 binding to CD4 eventually
leads to viral/target cell membrane fusion and entry of viral replicationmachinery. Importantly, this
early research clearly established that an essential cofactor for HIV entry was missing as CD4 alone
did not support HIV infection. While many teams all over the world were trying unsuccessfully to
identify such CD4 cofactor(s) enabling productive infection by HIV, scientist working in the field
of chemokines were making tremendous progress identifying new chemokines and receptors and
elucidating their biological roles.
Among them, Bernhard Moser at the Theodor-Kocher Institute in Bern, directed by Marco
Baggiolini, had isolated the cDNA for the orphan receptor LESTR, which shared typical charac-
teristics of G protein-coupled receptors (GPCRs) (2). Although the ligand for LESTR could not be
identified among a large number of identified chemotactic cytokines, the high expression in white
blood cells and the marked sequence relation to CXCR1/IL-8R1 and CXCR2/IL-8R2 suggested that
LESTR may be a novel receptor for an unknown chemokine. In a collaboration with Conrad Bleul,
a post-doctoral scientist in Tim Springer’s laboratory at Harvard University, Bernhard obtained
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preliminary evidence indicating that LESTR is the selective
chemokine receptor for the so-called Pre-B-cell growth-
stimulating factor/stromal cell-derived factor 1 (PBSF/SDF-
1/CXCL12), a member of the C–X–C subfamily, which was
originally cloned by two independent groups (3, 4). This highly
conserved chemokine turned out to have an essential (non-
redundant) role in B cell lymphopoiesis as well as the normal
development of the heart, the vasculature, and the brain. The
characterization of tissue expression of CXCL12/SDF-1 was
first shown in mice and we provided the first tissue expression
mapping in humans (5). In keeping with the high degree of
homology, the mouse sample of active CXCL12/SDF-1 that
Conrad Bleul brought to the Theodor-Kocher Institute behaved
as an agonist on cells expressing human LESTR.
Another breakthrough in HIV research was announced in
early 1996 at a Keystone Symposium by Edward Berger from the
National Institute of Health in Bethesda who reported unpub-
lished findings about a novel cell fusion coreceptor allowing the
infection by T cell line-tropic (TCL-tropic or T-tropic) but not
macrophage-tropic (M-tropic) HIV-1 isolates when co-expressed
on CD4+ target cells. In the subsequent paper by Ed Berger’s
group (6), this fusion coreceptor was called “fusin” and turned
out to be identical to LESTR that Bernhard’s group was work-
ing on. The ground-breaking discovery by Ed Berger’s group
revealed the definitive link between the interaction of HIV-1
and its target cells and the rapidly expanding field of chemokine
receptors.
CXCL12/CXCR4 and HIV-1 Infection:
The Meeting Point
In early 1996, scientists from the Theodor-Kocher Institute have
already been engaged in collaborations with groups at the Pas-
teur Institute in Paris who were investigating host immune cell
responses to parasites and the “fusin” discovery led to joint efforts
of our laboratories in the new arena of HIV research. This was the
beginning of a very fruitful and effective collaboration between
the scientists at the Theodor-Kocher Institute in Bern and our
department at the Pasteur Institute in Paris.
Thus, we immediately confirmed Bernhard’s findings about
LESTR being the specific receptor for CXCL12/SDF-1 using
both CHO cell lines transduced to express LESTR and human
leukocytes, including neutrophils, monocytes, and T lympho-
cytes. In all these cell types, CXCL12/SDF-1-induced robust
chemotaxis and intracellular Ca2+ responses, which are typical
responses seen with chemokines binding of cognate receptors.
Simultaneously, our findings were confirmed by Conrad Bleul
at Harvard University and, consequently, LESTR was renamed
as CXCR4, the fourth CXC chemokine receptors to be identi-
fied. Also, both groups obtained simultaneously evidence that
CXCL12/SDF-1 prevented selectively the infection by T-tropic
HIV isolates (laboratory adapted or primary) but was unable to
prevent infection of activated T lymphocytes by M-tropic viral
isolates (7, 8). However, as we demonstrated, CC chemokines
CCL3/MIP-1α, CCL4/MIP-1β, and CCL5/RANTES were unable
to block infection by T-tropic isolates thus proving the spe-
cific and selective inhibition by CXCL12/SDF-1 for this type
FIGURE 1 | Structure and mode of action of CXCL12/SDF-1 in HIV-1
infection. (A) Ribbon structure of human CXCL12/SDF-1α. The two disulfur
bonds are indicated in yellow (9). N, amino-terminus; C, carboxy-terminus. (B)
Human cells expressing CD4 and CXCR4 infected or not with an X4 HIV-1
isolate in the presence of SDF-1/CXCL12 or RANTES/CCL5. Infected cells
are visualized by β-galactosidase staining.
of viruses (Figure 1). Moreover, Conrad Bleul’s work demon-
strated that only CXCL12/SDF-1 including an intact amino-
terminal domain was active as suppressor factor for infection
by T-tropic viruses, indicating that the amino-terminal domain
in CXCL12/SDF-1 was required for both activation of CXCR4
and inhibition of T-tropic HIV-1 species. This experiment sug-
gested that CXCL12/SDF-1 could inhibit HIV infection by steric
hindrance of viral pg120 binding to CXCR4. We also showed
that CXCL12/SDF-1 blocked T-tropic HIV-1 infection at an early
step without affecting the rest of the HIV-1 life cycle by set-
ting up two complementary experiments (7). First, we demon-
strated that CXCL12/SDF-1 potently prevented the accumulation
newly reverse-transcribed HIV proviral DNA from the genomic
viral RNA, a mandatory process required for productive infec-
tion. Second, using HIV-1 particles whose envelope glycopro-
tein was replaced by the one from vesicular stomatitis virus,
which enables infection in a CD4- and coreceptor-independent
manner, we proved that CXCL12/SDF-1 failed to inhibit the
viral replication (occurring after viral entry). Both sets of find-
ings described above were published as back-to-back papers in
August 1996.
Obviously, CXCL12/SDF-1 was an excellent new target for the
development of novel inhibitors of infection by T-tropic HIV-1
species. Based on a collaboration that included Ian Clark-Lewis
from the University of British Columbia, we carried out detailed
structure–function studies and came up with a two-site model for
binding of CXCL12/SDF-1 to CXCR4, which became a general
a model for chemokine binding to their cognate receptors (9).
Similar work with CCL5/RANTES led to the identification of
CCR5 derivatives that failed to induce chemokine responses in
leukocytes yet retained the ability to block HIV-1 entry of M-
tropic but not T-tropic viruses (10). Simultaneously, we reported
that the anti-HIV-1 blocking activity of CXCL12/CXCL12 criti-
cally involved the cell surface depletion of CXCR4, a phenomenon
that was mediated by the intracellular carboxy-terminal region of
CXCR4 in a G protein-independent fashion (11).
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Following the Track: Chemokines and
HIV-1 Some Years Later
The accumulation of native chemokines that bind CCR5 with
high affinity (R5-CHKs) into the anatomical sites of HIV repli-
cation suggests that they could act as a natural barrier against
HIV infection, both by displacing the viral envelope glycoprotein
gp120 from binding to CCR5 and by promoting CCR5 endo-
cytosis. However, the concentration of R5-CHKs required to
inhibit R5 HIV-1 primary strains in primary CD4 cell targets
exceed by several orders of magnitude the receptor Ksd value
and chemotaxis-induction, a G-protein-dependent mechanism.
A possible explanation for this intriguing phenomenon is now
provided by recent work from our laboratory (12). We showed
that different CCR5 conformations at the cell surface are dif-
ferentially engaged by R5-CHKs and gp120, making R5-CHKs
weaker inhibitors of HIV infection than would be expected from
their binding affinity constants for CCR5. These distinct CCR5
conformations rely on CCR5 coupling to G-proteins. While R5-
CHKs bind with high affinity (Kd < 1 nM) to active conforma-
tions of CCR5 coupled to nucleotide-free G-proteins (NFG),
gp120/HIV-1 does not discriminate between NFG-protein cou-
pled an uncoupled CCR5. Interestingly, the antiviral activity
of R5-CHKs is G-protein independent, suggesting that inactive
CCR5, which are of low affinity for R5-CHKs, represent a portal
for viral entry. This is reminiscent of infection by R5 HIV-1,
which occurs also in a G-protein-independent fashion (13). Fur-
thermore, R5-CHKs are weak inducers of CCR5 endocytosis, as
is revealed by their potencies in the submicromolar range for
inducing endocytosis reflecting their low-affinity constant value
for NFG-protein-uncoupled receptors. Abolishing CCR5 interac-
tion with NFG-proteins eliminates high-affinity binding of R5-
CHKs but preserves receptor endocytosis, indicating that R5-
CHKs preferentially endocytose low-affinity receptors. These data
are consistent with HIV-1 evading R5-CHK inhibition by exploit-
ing CCR5 conformations that are weakly recognized by native
chemokines, named “spare receptors” that are unlikely to take
part in R5-CHKs-mediated functional responses. Importantly,
and in contrast to native chemokines, some RANTES/CCR5
antagonists and agonist analogs displaying improved anti-HIV-1
activity recognize this fraction of CCR5 receptors, thus proving
the importance of blocking “spare receptors” for preventingHIV-1
infection (14).
By sharp contrast, the affinity of CXCL12/SDF-1 for CXCR4
correlates well with its HIV-1 inhibitory activity and its ability to
induce CXCR4 internalization. This property could explain the
selective CXCR4 down-modulation on intestinal lymphocytes in
response to local CXCL12 constitutively produced by gut epithelia
(15). Mucosal epithelia are a site of prominent HIV-1 replication
and local CXCL12/SDF-1 could in part explain the observed
predominance of M-tropic HIV-1 variants, which are not affected
by CXCL12/SDF-1.
Conclusion
The seminal work reported by the laboratories of Paolo Lusso
and Ed Berger initiated an unprecedented storm of collabora-
tive activities across the fields of chemokine and HIV research.
It is now firmly established that CCR5 and CXCR4 are the
principal coreceptors for M-tropic and T-tropic HIV-1 variants
(also referred to as R5 and X4 HIV variants), respectively. Mar-
aviroc, a CCR5-specific antagonist, is currently used in the treat-
ment of HIV infected individuals. Still, many questions remain.
For instance, R5 HIV-1 viruses are transmitted and propa-
gated preferentially during the early and asymptomatic stages
of infection while viruses showing CXCR4 tropism (X4 HIV-1
and, mainly, dual tropic X4R5 HIV-1) emerge progressively and
become detectable in roughly 40–50% of infected people at later
stages of the infection or during the AIDS phase. This apparent
paradox is still unresolved, as CXCR4 expression is constitutive
and ubiquitous, including most nucleated cells and, most notably,
CD4+ T cells. By clear contrast, expression of CCR5 is restricted
to activated effector T cells, which are a minor subset of T cells
in peripheral blood, and dendritic cells indicating that target cells
for R5 HIV-1 are much more limited. The causes underlying this
phenomenon are likely multifactorial and a number of possible
mechanisms had been proposed. The fact that X4 HIV-1 viruses
rapidly emerge in a significant proportion of HIV-1-infected
patients treated by the CCR5-specific antagonist maraviroc and
spontaneously regress as the administration of this drug is inter-
rupted, suggests that a certain degree of competition between R5
and X4 HIV-1 viruses exists.
The hectic research activities carried out during the first half
of 1996 was due to intense collaborations set up by research
teams working in, a priori, separated fields such as molecular
virology, chemokine biology, or GPCR pharmacology. Within
this setting, the real contribution of chemokine and chemokine
receptor research to the new field was that it progressively imple-
mented and transformed our basic knowledge of HIV cell tropism
into a detailed view and understanding of the complex molecular
mechanisms of HIV entry leading to novel therapeutic strategies
for blocking HIV infection.
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